APA (7th ed.) Citation

E, B., O, A., T, E., M, B., G, B., J, C., . . . M, N. (2026). A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. Oncotarget, 17(1), 291. https://doi.org/10.18632/oncotarget.28892

Chicago Style (17th ed.) Citation

E, Bivens, et al. "A Randomized Double-blind Placebo-controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Squamous Cell Carcinoma Recurrence." Oncotarget 17, no. 1 (2026): 291. https://doi.org/10.18632/oncotarget.28892.

MLA (9th ed.) Citation

E, Bivens, et al. "A Randomized Double-blind Placebo-controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Squamous Cell Carcinoma Recurrence." Oncotarget, vol. 17, no. 1, 2026, p. 291, https://doi.org/10.18632/oncotarget.28892.